Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
In the big pharma sector, the best buy is AstraZeneca at prices below $56
11:48pm, Monday, 28'th Mar 2022 Invezz
GlaxoSmithKline PLC (LON:GSK), Johnson & Johnson (FRA:JNJ), and AstraZeneca PLC (LON:AZN) are certainly the best in the big pharma industry. As the companies compete in the drug wars, investors only w
In the big pharma sector, the best buy is AstraZeneca at prices below $56
07:48pm, Monday, 28'th Mar 2022
GlaxoSmithKline PLC (LON:GSK), Johnson & Johnson (FRA:JNJ), and AstraZeneca PLC (LON:AZN) are certainly the best in the big pharma industry. As the companies compete in the drug wars, investors only w
AstraZeneca (AZN) Gets EU Nod for COVID-19 Antibody Cocktail
04:31pm, Monday, 28'th Mar 2022 Zacks Investment Research
The European Commission approves AstraZeneca's (AZN) Evusheld for the pre-exposure prophylaxis of COVID-19 infection in a broad patient population.
AstraZeneca (AZN) Gets EU Nod for COVID-19 Antibody Cocktail
01:33pm, Monday, 28'th Mar 2022
The European Commission approves AstraZeneca's (AZN) Evusheld for the pre-exposure prophylaxis of COVID-19 infection in a broad patient population.
Are These 2 Rivals Beating Pfizer and Moderna?
10:00am, Monday, 28'th Mar 2022 The Motley Fool
They're winning when it comes to orders.
AstraZeneca's COVID drug bags EU approval
05:13am, Monday, 28'th Mar 2022
AstraZeneca PLC (LSE:AZN) has received EU marketing authorisation for its Evusheld antibody combination for the prevention of COVID-19 in a broad population. The Cambridge, England-based firm said the
Nuformix says patent application for reformulated AstraZeneca blockbuster has progressed to publication phase
02:56am, Monday, 28'th Mar 2022
Nuformix PLC (LSE:NFX) said its patent application for key asset NXP004 had progressed to the publication phase. Following this, it was able to reveal that NXP004 is a novel, or new formulation of Ola
Which Company Has the Biggest COVID Program? The Answer Isn't Moderna.
12:00pm, Sunday, 27'th Mar 2022 The Motley Fool
Another player has stuffed its pipeline with many coronavirus candidates.
AstraZeneca's (AZN) Imfinzi Misses Goal in Cervical Cancer Study
06:24pm, Friday, 25'th Mar 2022 Zacks Investment Research
AstraZeneca's (AZN) blockbuster drug Imfinzi fails to achieve progression-free survival endpoint with statistical significance in cervical cancer patients during a late-stage study.
AstraZeneca's (AZN) Imfinzi Misses Goal in Cervical Cancer Study
03:48pm, Friday, 25'th Mar 2022
AstraZeneca's (AZN) blockbuster drug Imfinzi fails to achieve progression-free survival endpoint with statistical significance in cervical cancer patients during a late-stage study.
Pfizer's (PFE) RSV Jab Gets Another Breakthrough Therapy Tag
03:03pm, Friday, 25'th Mar 2022 Zacks Investment Research
The FDA bestows another Breakthrough Therapy status to Pfizer's (PFE) RSV vaccine candidate, RSVpreF, for the prevention of RSV in older adults.
3 Top Healthcare Stocks to Buy for the Long Haul
02:00pm, Friday, 25'th Mar 2022 The Motley Fool
A couple of these stocks have been down big this year and could be overdue for a rally.
ISA millionaires up by two-thirds and by investing in Lloyds Bank and AstraZeneca
11:38am, Friday, 25'th Mar 2022
Lloyds Bank, AstraZeneca and Unilever are apparently three of the ways you can become an ISA millionaire, according to the latest study of the portfolios of its customers by Hargreaves Lansdown. The n
Should You Buy This Big Pharma Stock?
03:30pm, Thursday, 24'th Mar 2022 The Motley Fool
AstraZeneca possesses a stacked, commercialized drug portfolio. And its pipeline of drug candidates is just as enviable.
Should You Buy This Big Pharma Stock?
11:30am, Thursday, 24'th Mar 2022
AstraZeneca possesses a stacked, commercialized drug portfolio. And its pipeline of drug candidates is just as enviable.
